News Posts List
Afinitor Cancer Drug Rejected by U.K. Cost Agency
02/09/2010
The U.K.s health-cost regulator rejected Novartis AGs tumor treatment Afinitor for advanced kidney cancer in a draft ruling that is likely to curtail its use among publicly insured patients.
Health-related quality of life in patients with metastatic renal cell carcinoma
02/09/2010
Patients treated with sunitinib in this study had improved HRQoL, compared with patients treated with IFNalpha. Treatment differences within the US cohort did not differ from those within the EU cohort.
New data on renal cell carcinoma epidemiology
02/09/2010
A new study, 'Prognostic significance of Gremlin1 (GREM1) promoter CpG island hypermethylation in clear cell renal cell carcinoma,' is now available.
Prometheus Makes Deal to Sell Kidney Cancer Drug
02/09/2010
A deal struck with Swiss pharmaceutical giant Novartis AG will allow San Diego-based Prometheus to begin selling skin and kidney cancer drug Proleukin [IL-2] in the United States
Microscopic tumor necrosis and survival after curative surgery for renal cell carcinoma
02/09/2010
Tumor necrosis is a potential marker of recurrence and survival after surgery for renal cell carcinoma. We determined whether a correlation exists between the amount (not just the presence/absence) of tumor necrosis, and metastasis-free, disease specific and overall survival after surgery for renal cell carcinoma.
Could toenail clippings be key to understanding kidney cancer risks?
02/09/2010
Research will focus on identifying to what extent well water contaminated by arsenic is contributing to high rates of bladder and kidney cancer.
Radio-frequency ablation 'cooking' kidney cancer tumors
02/08/2010
"It basically cooks the tumor to death," said Dr. Peter Julien, Chief of Thoracic Imaging at Cedars-Sinai Medical Center.
Caregivers need help as much as the seriously ill
02/08/2010
About 15 years ago, Robert's health began to fail. He had to retire after several heart attacks. And then it was kidney cancer, and then it was cancer of the esophagus
Oral therapy slows progression of advanced kidney cancer
02/06/2010
Pazopanib (Votrient) appears to delay disease progression by 54% in patients with advanced renal cell carcinoma, according to a study by Italian researchers.
News Feed